Stirling reports positive preliminary trial results
Tuesday, 30 November, 2004
Stirling Products (ASX: STI) has reported that preliminary results from the trials of its lead product ST810 (R-salbutamol) in pigs indicate significantly higher potency than expected, with economic viability at the lowest dose tested.
Final results from the trial, which was conducted in the US by the USDA's Swine Research Unit, will be released early in 2005. The trial was designed to measure physiological and behavioural parameters including weight gain, feed conversion, increase in lean meat and decrease in fat content.
New drug to prevent migraine claimed to work straight away
People taking atogepant showed improvement on assessments of how much migraine impaired their...
Your stool can reveal your risk of cardiovascular disease
Certain faecal proteins have been linked to deadly cardiovascular conditions. A connection...
Targeting the stress system reduces Parkinson's tremors
The commonly used Parkinson's drug levodopa usually helps with tremors, but it tends to be...
